Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078772 | 1.00 | MEN1 (0.45) | MEN1KMT2ACCR8P2RY12GAA | |
| SCHEMBL3086546 | 0.83 | ALDH1A1 (0.42) | MEN1KMT2AP2RY12GAAALDH1A1 | |
| SCHEMBL3086550 | 0.83 | ALDH1A1 (0.42) | MEN1KMT2AP2RY12GAAALDH1A1 | |
| SCHEMBL3087627 | 0.83 | OPRD1 (0.39) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL3071759 | 0.78 | MAPK1 (0.40) | MEN1KMT2AGAATSHRALDH1A1 | |
| SCHEMBL3071763 | 0.78 | MAPK1 (0.40) | MEN1KMT2AGAATSHRALDH1A1 | |
| SCHEMBL3077446 | 0.78 | ALDH1A1 (0.47) | MEN1KMT2AGAAALDH1A1MAPT | |
| SCHEMBL3077450 | 0.78 | ALDH1A1 (0.47) | MEN1KMT2AGAAALDH1A1MAPT | |
| SCHEMBL12430160 | 0.70 | POLB (0.41) | KMT2AGAATSHRALDH1A1CHRM1 | |
| SCHEMBL12430153 | 0.69 | BRD4 (0.45) | MEN1KMT2AALDH1A1MAPTCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795436-B2 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | HTR2B, HTR2C, HTR1A | MEN1 2162/4885KMT2A 3546/4885CCR8 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.